Physician profile
Harini Rao
NPI 1245486141
$521.09
in general payments reported to CMS, 2019-2025
11 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.25 · 2021: $59.20 · 2022: $14.31 · 2023: $64.55 · 2024: $199 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emmaus Medical, INC. | $148.73 | 2019-2024 | Endari |
| Pfizer INC. | $132.60 | 2023-2024 | |
| Adaptive Biotechnologies Corporation | $44.57 | 2024-2025 | Clonoseq |
| Azurity Pharmaceuticals, INC. | $35.70 | 2024-2025 | Katerzia, Xatmep |
| Agios Pharmaceuticals, INC. | $35.34 | 2025 | Pyrukynd |
| Springworks Therapeutics, INC. | $29.86 | 2025 | Gomekli |
| Astellas Pharma US INC | $23.97 | 2025 | Cresemba |
| Medunik USA INC. | $19.78 | 2025 | Siklos |
| Servier Pharmaceuticals LLC | $18.98 | 2024 | |
| Day One Biopharmaceuticals | $18.30 | 2025 | Ojemda |
| Duchesnay USA Incorporated | $13.26 | 2023 | Pheburane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harini Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.